Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | RNASEL | Q05823 | 6/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25816144 | 0.90 | ADORA1 (0.41) | ADORA1RNASELNT5E | |
| SCHEMBL25816125 | 0.84 | ADORA1 (0.43) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23619355 | 0.84 | ADORA1 (0.43) | ADORA1RNASELNT5E | |
| SCHEMBL23619399 | 0.81 | P2RY1 (0.52) | ADORA1RNASELP2RX1P2RX3P2RX4 | |
| SCHEMBL23619346 | 0.79 | ADORA1 (0.46) | ADORA1RNASELNT5E | |
| SCHEMBL25812243 | 0.78 | ADORA1 (0.44) | ADORA1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23619226 | 0.78 | ADORA1 (0.54) | ADORA1RNASELNT5E | |
| SCHEMBL23619323 | 0.76 | NT5E (0.45) | ADORA1RNASELNT5E | |
| SCHEMBL18522154 | 0.74 | ADORA1 (0.44) | ADORA1 | |
| SCHEMBL23619432 | 0.73 | ADORA1 (0.48) | ADORA1RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA1 33/4885PI4KA 2362/4885PI4K2B 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.